HUTCHMED clears CMC rejection to win dual China approvals for SYK inhibitor sovleplenib
HUTCHMED (HKEX: 00013; NASDAQ: HCM) won simultaneous NMPA approvals (CXHS2600027, CXHS2600058) on Nov 19, 2026 for SYVIK (sovleplenib) in adult ITP and wAIHA 11 months after an impurity rejection.
HUTCHMED (China) Limited (HKEX: 00013; NASDAQ/AIM: HCM) announced on November 19, 2026 (SEC Form 6-K Exhibit 99.2) that China’s National Medical Products Administration (NMPA) has granted simultaneous marketing approvals for two New Drug Applications of its oral spleen tyrosine kinase (SYK) inhibitor SYVIK (sovleplenib / HMPL-523, Chinese trade name Saiweike): adult chronic primary immune thrombocytopenia (ITP) after an insufficient response to at least one prior therapy (CXHS2600027), and adult warm antibody autoimmune hemolytic anemia (wAIHA) after an insufficient response to prior corticosteroid therapy (CXHS2600058). The dual clearance makes sovleplenib the first SYK inhibitor approved in China and the first oral targeted therapy cleared in the country for wAIHA—completing an 11-month regulatory recovery after a December 30, 2025 NMPA non-approval notice over manufacturing impurity thresholds stalled the original January 2024 ITP filing and prompted HUTCHMED to withdraw its U.S. and European Phase 1 ITP trial (NCT06291415).
While HUTCHMED retains 100% worldwide rights to sovleplenib and secured U.S. Food and Drug Administration (FDA) Orphan Drug Designations for ITP (October 29, 2026) and wAIHA (November 5, 2026), the simultaneous China approvals arrive six days after the November 14 publication of the 2026 National Reimbursement Drug List (NRDL), meaning SYVIK will launch in China as a self-pay and commercial-insurance product throughout 2027 ahead of the mid-2027 NRDL negotiation window.
How a two-indication priority review recovered from the December 2025 impurity rejection
The regulatory trajectory of sovleplenib illustrates both the tightening of Chemistry, Manufacturing, and Controls (CMC) impurity standards at the NMPA’s Center for Drug Evaluation (CDE) and the speed of priority-review resubmissions once analytical and process controls are remediated:
- Initial
ITPfiling and December 2025CMCrejection (CXHS2400006): HUTCHMED submitted its first China NDA forsovleplenibin primaryITPon January 11, 2024 (CNINFO filing1218850747.PDF) under Priority Review, backed by the Phase 3ESLIM-01trial (NCT05029635). After nearly 24 months of review, theNMPAissued a non-approval notice (Yaopin Tongzhijian) on December 30, 2025 because batch impurity limits did not meet tightenedCDEspecifications. - Nine-month resubmission-to-approval sprint (
CXHS2600027&CXHS2600058): After completingCMCimpurity-reduction work, HUTCHMED re-qualified for Priority Review on January 8, 2026 and resubmitted theITPNDA (CXHS2600027) on February 10, 2026. In parallel, following positive Phase 3 topline results inwAIHA(ESLIM-02,NCT05535933) announced on January 7, 2026 and Breakthrough Therapy Designation in March 2026, theCDEaccepted thewAIHANDA (CXHS2600058) with Priority Review on April 29, 2026. TheNMPAcleared both applications together on November 19, 2026—9.3 months after theITPrefiling and 6.7 months after thewAIHAacceptance.
Pivotal data across ESLIM-01 (ITP) and ESLIM-02 (wAIHA) against global FcRn, BTK, and SYK benchmarks
Both approved indications are anchored by randomized, double-blind, placebo-controlled Phase 3 trials in China (300 mg oral once daily for 24 weeks) published in The Lancet Haematology and presented at the European Hematology Association (EHA) 2026 Congress (June 12, 2026 filing):
| Trial / Indication | Design & Baseline Population | Primary Endpoint (Durable Response) | Overall Response & Onset | Rescue Therapy & Key Subgroup Data | Grade ≥3 TEAEs & Discontinuations |
|---|---|---|---|---|---|
ESLIM-01 (NCT05029635 / CTR20211537) — Adult Chronic Primary ITP |
Randomized 2:1 (n = 188: 126 sovleplenib 300 mg QD vs. 62 placebo, 24 wks); median 4 prior lines; 74.6% had prior TPO / TPO-RA |
48.4% (61/126) vs. 0% (0/62) (p < 0.0001, platelet count ≥ 50 × 109/L on ≥ 4 of 6 scheduled visits in Weeks 14–24) |
Weeks 0–12 ORR: 68.3% vs. 14.5%; Weeks 0–24 ORR: 70.6% vs. 16.1% (p < 0.0001); median time to response 8 days vs. 30 days |
Prior ≥ 4 lines DRR: 47.7% vs. 0%; prior TPO/TPO-RA subgroup DRR: 46.8% vs. 0% (p < 0.0001) |
Grade ≥ 3 TEAEs: 25.4% vs. 24.2%; significant improvement in SF-36 physical function and fatigue (p < 0.05) |
ESLIM-02 (NCT05535933 / CTR20221854) — Adult Relapsed/Refractory wAIHA |
Randomized Phase 2/3 (Phase 3 double-blind 24 wks, 300 mg QD vs. placebo in post-glucocorticoid primary or secondary wAIHA) |
66% vs. 15% (p < 0.0001, durable hemoglobin response during Weeks 5–24) |
24-week ORR (Hb ≥ 100 g/L with ≥ 20 g/L increase from baseline without rescue): 70% vs. 22% (p < 0.0001); median onset 3.1 weeks vs. 6.3 weeks |
Rescue therapy required: 16% vs. 54%; RBC transfusion: 11% vs. 43%; steroid/concomitant taper or stop: 50% vs. 15% (p = 0.003); prior rituximab DRR: 69% vs. 16% (p = 0.0022) |
Grade ≥ 3 TEAEs: 43% vs. 59% (most common: worsening wAIHA 18% vs. 43%, URI 2% vs. 11%); 0% treatment-related deaths or discontinuations |
Placing sovleplenib against global and domestic hematology competitors highlights two distinct commercial dynamics:
- In
wAIHA,sovleplenibcaptures an uncontested first-mover position in China: Globally, the only other first-generationSYKinhibitor—Rigel Pharmaceuticals’ (NASDAQ: RIGL)fostamatinib(Tavalisse, approved by the U.S. FDA forITPin 2018)—failed its Phase 3FORWARDtrial inwAIHA(NCT03764618) in June 2022 after an elevated placebo response in Eastern European sites and has never been approved in China. In the United States, Johnson & Johnson (NYSE: JNJ) won the first FDA targeted approval inwAIHAin August 2026 with its intravenous anti-FcRnantibodynipocalimab(Imaavy), while Sanofi (EPA/NASDAQ: SNY) is advancing its oralBTKinhibitorrilzabrutinib(Wayrilz, FDA-approved forITPin August 2025) after reporting Phase 2bLUMINA 2wAIHAdata in October 2026. In China, where roughly 40,000 adults live withwAIHAand off-label rituximab, splenectomy, and chronic steroids remain the only options,SYVIKis the first approved targeted therapy of any class. - In
ITP,sovleplenibenters a crowded Chinese second-line market but targets theTPO-RA-refractory pool: According toIQVIAfigures cited in HUTCHMED’s filings, China has roughly 430,000 prevalentITPpatients and 41,000 new diagnoses annually, with oralTPOreceptor agonists—including Hengrui’s (SSE: 600276)hetrombopag(Hengqu), Novartis’seltrombopag(Revolade), and Fosun Pharma’savatrombopag(Doptelet)—plus Zai Lab / argenx’s anti-FcRnefgartigimod(Vyvgart) already entrenched in the basicNRDL. Meanwhile, InnoCare Pharma (HKEX: 09969;SSE: 688428) completed its China Phase 3ITPtrial for theBTKinhibitororelabrutinib(Yinuokai,NCT05124028) and is preparing an sNDA.Sovleplenib’s clinical wedge inITPis its46.8%durable response rate (versus0%on placebo) in the74.6%ofESLIM-01patients who had already failedTPO/TPO-RAtherapy.
Why HUTCHMED withdrew its U.S./EU sovleplenib trial and signaled a next-generation SYK NCE for out-licensing
For cross-border business development (BD) observers, the most consequential contrast lies between sovleplenib’s domestic commercial launch and its overseas clinical status.
On ClinicalTrials.gov, HUTCHMED’s multicenter U.S., German, Spanish, Norwegian, and Australian Phase 1 trial of HMPL-523 in adult ITP (NCT06291415) is listed as WITHDRAWN with 0 patients enrolled. Because sovleplenib (compound 225 in PCT patent WO2012167733A1) claims an earliest priority window from 2011–2012, the 2024–2025 CMC delay in China compressed the remaining composition-of-matter patent runway outside China before global Phase 3 trials in ITP or wAIHA could even start.
Rather than funding late-stage Western trials on an aging patent clock, HUTCHMED CEO and CSO Weiguo Su, Ph.D., noted during recent investor briefings that the company can advance a new chemical entity (NCE) next-generation SYK inhibitor with full patent life into U.S. and global clinical development—using the clinical validation of ESLIM-01 and ESLIM-02 plus the October and November 2026 FDA Orphan Drug Designations (which confer 7-year U.S. orphan market exclusivity upon approval independently of composition-of-matter patents) to evaluate strategic partnering pathways alongside its emerging Antibody-Targeted Therapy Conjugate (ATTC) oncology platform (HMPL-A251, HMPL-A580, and HMPL-A830).
The next records that will determine SYVIK’s commercial trajectory and global value are initial provincial procurement (guawang) launch pricing in China across 300 mg tablet packs in Q1 2027; whether HUTCHMED prices sovleplenib for entry into the 2027 NRDL negotiation cycle (for effect January 1, 2028) across both ITP and wAIHA simultaneously; and whether the company files a U.S. IND or discloses an ex-China licensing agreement for either orphan-designated sovleplenib in wAIHA or a follow-on SYK new chemical entity in 2027.